Metoprolol succinate efficacy and side effects
Pro Research Analysisby 
Searched over 200M research papers
Efficacy of Metoprolol Succinate in Hypertension, Arrhythmias, and Angina
Metoprolol succinate, a beta-blocker, has shown strong efficacy in treating mild to moderate essential hypertension, with a marked effective rate of 60% and a total effective rate of 85% in one study, significantly reducing both systolic and diastolic blood pressure . In patients with post-myocardial infarction ventricular arrhythmias, metoprolol succinate extended-release tablets improved clinical indicators such as QT dispersion and heart rate, achieving a higher total clinical effectiveness (95.24%) compared to alternative treatments, and also resulted in a lower incidence of adverse reactions . For coronary heart disease patients with silent myocardial ischemia, metoprolol succinate reduced the frequency and duration of ischemic episodes and improved heart rate variability, with no reported side effects .
In the context of vasospastic angina, metoprolol succinate was more effective than metoprolol tartrate in reducing the incidence of clinically significant angina attacks, although both forms showed similar rates of major cardiovascular events . When combined with other agents such as trimetazidine or Wenxin Granules, metoprolol succinate further improved angina control and arrhythmia management, with high effectiveness and safety Huang2020Zhao2021.
Efficacy in Arrhythmias: Limitations and Specific Populations
The efficacy of metoprolol succinate in treating idiopathic, frequent, monomorphic premature ventricular contractions (PVCs) is limited. Only about 14% of patients experienced a good response, while 61% had a poor response, and approximately 25% experienced a pro-arrhythmic effect, especially in those with a high PVC burden . In patients with Eisenmenger syndrome, metoprolol succinate did not improve exercise capacity and was associated with a higher rate of clinical worsening, mainly due to heart failure .
Side Effects and Safety Profile of Metoprolol Succinate
Metoprolol succinate is generally well tolerated. In hypertension and coronary heart disease studies, side effects were minimal, with only mild bradycardia reported in a small number of cases Jianghong2007Lian-Wang2008. In arrhythmia studies, side effects or intolerance occurred in about 5.5% of patients . In post-myocardial infarction patients, the incidence of adverse reactions was low (4.76%) compared to alternative treatments .
Rare but serious side effects have been reported, such as erythema multiforme, a skin reaction, in isolated cases . Animal studies at very high doses showed toxicity affecting the heart, liver, kidney, and intestine, but these doses far exceed those used in clinical practice .
Comparative Effectiveness and Economic Considerations
While metoprolol succinate and metoprolol tartrate are similarly effective in preventing major cardiovascular events, succinate may be superior in reducing angina attacks. However, metoprolol tartrate may offer greater pharmacoeconomic advantages .
Conclusion
Metoprolol succinate is effective and generally safe for treating hypertension, post-myocardial infarction arrhythmias, and angina, especially when used in combination with other agents. Its efficacy in idiopathic PVCs and Eisenmenger syndrome is limited, and rare but serious side effects can occur. Overall, it remains a valuable option in cardiovascular therapy, with a favorable safety profile in most patient populations.
Sources and full results
Most relevant research papers on this topic
Therapeutic effect of Metoprolol Succinate Sustdined-release tablets on mild to moderate essential hypertension
Metoprolol-SR is effective and well-tolerated for patients with mild to moderate essential hypertension, reducing SBP and DBP with minimal side effects.
Toxicity studies of metoprolol succinate after repeated oral exposure in albino rats
Metoprolol succinate causes mild CNS depression and adverse effects on body weights at 1000 mg/kg, with mortality observed at doses above 500 mg/kg, and is primarily cardiotoxic in rats.
Comparative evaluation of the effectiveness of metoprolol succinate and metoprolol tartrate in patients with vasospastic angina
Metoprolol succinate has a significant advantage in reducing clinically significant angina attacks, but no significant difference in cardiovascular events or death between the two drugs.
Clinical Efficacy of Metoprolol Succinic Acid Sustained Release Tablets Combined with Trimetazidine in the Treatment of Gastrointestinal Tumors with Angina Pectoris
Metoprolol succinate sustained-release tablets combined with trimetazidine improve angina pectoris treatment efficacy and are safe for clinical use in gastrointestinal tumors with angina pectoris.
DOI
Therapeufic efficacy of metoprolol succinate sustained-release tablets on silent myocardial ischemia and heart rate variability with coronary heart disease
Metoprolol-SR tablets effectively reduce silent myocardial ischemia and improve heart rate variability in patients with coronary heart disease, without causing side effects.
Efficacy of Metoprolol Succinate Sustained Release Tablets Combined with Wenxin Granules in the Treatment of Coronary Heart Disease Arrhythmia
Metoprolol succinate sustained-release tablets combined with Wenxin Granules significantly improves dynamic electrocardiogram indexes, clinical efficacy, and safety in treating coronary heart disease patients with arrhythmia.
DOI